Navigation Links
Drug Failed to Reduce Heart Attack Risk After Bypass
Date:4/1/2008

MC-1 had no benefit for postoperative stroke, atrial fibrillation or kidney function

TUESDAY, April 1 (HealthDay News) -- Researchers found that giving patients MC-1, a naturally occurring metabolite of vitamin B6, before and after bypass surgery didn't reduce the risk of heart attack or cardiovascular death.

"Coronary artery bypass graft (CABG) surgery is one of the most important therapeutic options for relieving angina and improving survival and quality of life in patients with multi-vessel coronary artery disease," the Duke University scientists wrote. "It is the most commonly performed cardiac surgical procedure in the world, and, in 2005, more than 250,000 CABG procedures were performed in the United States."

But CABG surgery can lead to serious complications such as heart attack, recurrent angina, kidney problems, stroke and death. Previous research suggested that MC-1 may lower the risk of heart attack or death in high-risk patients.

A new phase 3 multi-center, randomized trial of MC-1 included 3,023 intermediate- to high-risk patients undergoing CABG surgery with cardiopulmonary bypass. It found that cardiovascular death or nonfatal heart attack 30 days after surgery occurred in 140 of 1,510 patients (9.3 percent) who received MC-1 and in 133 of 1,486 patients (9.0 percent) who received a placebo.

All-cause death was 1 percent in the MC-1 group and 0.3 percent in the placebo group at four days, and 1.9 percent in the MC-1 group and 1.5 percent in the placebo group at 30 days.

Both groups had similar levels of postoperative stroke, atrial fibrillation, kidney function, and intensive care unit and hospital lengths of stay.

The findings show that "among intermediate- to high-risk patients undergoing CABG surgery, MC-1, 250 mg/d, given immediately before and for 30 days following surgery did not reduce cardiovascular death or nonfatal (heart attack)," the study authors wrote. "My
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. UFE Highly Effective in Cases Where Focused Ultrasound to Treat Uterine Fibroids Failed
2. PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy
3. Fallout From Failed AIDS Vaccine Could Dampen Research
4. Safe, Green Insecticides Can Reduce Chemical Exposure in Homes and Gardens
5. Illinois Radiologists Self-Edit Reports, Reduce Turnaround Time with SpeechQ for Radiology(TM)
6. Evanston-Northwestern Study Proves Effectiveness of MRSA Screening to Reduce Hospital Infections
7. Psychological intervention reduces postembolization pain
8. Aspirin Reduces Asthma Risk Among Older Women
9. Partnerships Report Highlights How Blue Cross Blue Shield of Michigan, Physicians and Hospitals Are Working to Save Lives, Improve Care, Reduce Costs
10. Low-Fat Dairy Reduces High Blood Pressure Risk
11. Late treatment with letrozole can reduce breast cancer recurrence risk
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug Failed to Reduce Heart Attack Risk After Bypass 
(Date:9/21/2014)... metastasize? Think of Sparta. , Ancient Greek warriors were ... the demands of battle on distant fields. Cancer cells ... a new study revealing previously unknown differences between cancer ... site, and those that travel to other organs. , ... is the primary cause of cancer-related death, understanding how ...
(Date:9/21/2014)... NY (PRWEB) September 21, 2014 ... develops, implements and supports electronic medical records (EMR) ... benefited from federal healthcare legislation during the past ... do so during the five years to 2019. ... Clinical Health Act established Medicare and Medicaid incentives ...
(Date:9/21/2014)... September 21, 2014 Originally approved ... 1996, GSK’s Flovent (fluticasone propionate) is a synthetic ... used for the maintenance treatment of asthma prophylactically ... in two formulations, Diskus and HFA, which received ... Flovent’s active ingredient, fluticasone propionate, can bind to ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 More ... have been added over the past month to ... allege serious cardiovascular injuries caused by the dialysis ... List updated on September 15th shows 2,089 cases ... U.S. District Court, District of Massachusetts. These claims ...
(Date:9/21/2014)... September 21, 2014 Developers and plugin ... have announced a new transition plugin entitled Transpack Vol. ... delivers high quality transitions that will add a level ... Austin, CEO of Pixel Film Studios. “Blurring the line ... definite game changer.” , Transpack Vol. 3 returns with ...
Breaking Medicine News(10 mins):Health News:Cancer cells adapt energy needs to spread illness to other organs 2Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 4Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 2Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 3Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 4Health News:Pixel Film Studios Released Transpack Vol. 3 Plugin Exclusively for Final Cut Pro X 2
... , , , ... design competition offering the chance to combine creativity with passion for a ... Oct. 26, 2009, participants can enter Passionately Pink-inspired T-shirt designs with messages ... drawing for a $100 Hanes gift card. In addition, a ...
... , RICHMOND, Calif., Aug. 18 ... announced plans to reduce operating expenses by eliminating certain staff ... Purdue Pharmaceutical Products to commercialize Intermezzo ((R) )(zolpidem tartrate ... , Glenn A. Oclassen, President and Chief Executive ...
... SAN DIEGO, Aug. 18 Aethlon Medical, Inc. ... at today,s 14th Annual Southern California Investor Conference being ... The conference is hosted by California Equity Research and ... life science, technology, media, and real estate/financial organizations. ...
... ... announced that the hemostatic HemCon Patch™ and HemCon® Bandage were ... Premier Purchasing Partners L.P., the group purchasing unit of Premier Inc. ... The agreement makes HemCon dressings available at pre-negotiated terms to all ...
... , , INDIANAPOLIS, ... as those relating to smoke and fire, there would be a ... special operations for the Alameda County Fire Department in California. "The ... addressing the problem adequately. A 2006 NFPA study reveals 87-percent of ...
... ... States Health Alliance Admitted to Talent Management Organization , ... Atkins, VA (PRWEB) August 18, 2009 -- The ... world-class companies, has two new members, Qwest, headquartered in Denver, Colorado, and Mountain States ...
Cached Medicine News:Health News:Hanes(R) and Susan G. Komen for the Cure(R) Inspire Creativity for a Cause 2Health News:Hanes(R) and Susan G. Komen for the Cure(R) Inspire Creativity for a Cause 3Health News:Hanes(R) and Susan G. Komen for the Cure(R) Inspire Creativity for a Cause 4Health News:Transcept Announces Plans to Reduce Expenses by Decreasing Staff Following Recent Completion of Purdue U.S. License and Collaboration Agreement 2Health News:Transcept Announces Plans to Reduce Expenses by Decreasing Staff Following Recent Completion of Purdue U.S. License and Collaboration Agreement 3Health News:Transcept Announces Plans to Reduce Expenses by Decreasing Staff Following Recent Completion of Purdue U.S. License and Collaboration Agreement 4Health News:Transcept Announces Plans to Reduce Expenses by Decreasing Staff Following Recent Completion of Purdue U.S. License and Collaboration Agreement 5Health News:Aethlon Medical to Present at Today's Southern California Investor Conference 2Health News:Hemostatic HemCon Dressings Selected by the Premier Healthcare Alliance for Hemostasis Products Contract 2Health News:Hemostatic HemCon Dressings Selected by the Premier Healthcare Alliance for Hemostasis Products Contract 3Health News:Cyanide Toxicity in Smoke Inhalation Victims - a Deadly but Treatable Poison 2Health News:Cyanide Toxicity in Smoke Inhalation Victims - a Deadly but Treatable Poison 3Health News:Leading Communications and Healthcare Firms Join TEDS Consortium 2Health News:Leading Communications and Healthcare Firms Join TEDS Consortium 3Health News:Leading Communications and Healthcare Firms Join TEDS Consortium 4
(Date:9/19/2014)... 2014 /PRNewswire-iReach/ -- "United States General ... key market data on the United ... report provides value, in millions of ... within market categories – Bronchoscopes, Laryngoscopes, ... Gastroscopes, Duodenoscopes, Laparoscopes, Hysteroscopes, Sinuscopes, Resectoscopes, ...
(Date:9/19/2014)... 19, 2014 According to ... (Cryotherapy, Heat, therapy, Hydrotherapy), Accessories (Posture Mirror, Exercise Ball), ... technologies - Global Forecast to 2019" published by ... reach $19,786.3 Million by 2019 from $14,240.0 Million ... 2014 to 2019. Browse 74 market ...
(Date:9/19/2014)... Merck (NYSE: MRK ), known as MSD outside ... , is teaming with celebrity chef and cookbook author Leticia Moreinos ... educational program encouraging Hispanics with type 2 diabetes to achieve better ... help reduce the risk of serious health problems. Hispanics in ... for developing type 2 diabetes than non-Hispanic white adults, and it ...
Breaking Medicine Technology:United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 4United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 5Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 3Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 5
... patients will be tested,to determine the prevalence of ... major cooperative effort between the Alpha-1 Foundation,and the ... principal investigator is Robert A. Sandhaus, MD, PhD, ... and Research Center,in Denver. Sandhaus is also the ...
... Dec. 6 DURECT Corporation,(Nasdaq: DRRX ... III trial for Remoxy,had successfully met its ... the U.S. Food and Drug Administration (FDA) ... investigational drug based on,DURECT,s patented ORADUR(TM) technology, ...
Cached Medicine Technology:Alpha-1 Foundation, AARC Cooperate on Study to Test 5,000 COPD Patients for Alpha-1 2Alpha-1 Foundation, AARC Cooperate on Study to Test 5,000 COPD Patients for Alpha-1 3Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy(TM) 2Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy(TM) 3Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy(TM) 4
... The FASTak Suture Anchor is a fully ... is inserted directly into bone without predrilling using ... Tear Drop Handle and Keyless Chuck. This implant ... well as other small anchor indications with very ...
... one step fixation of soft tissue to bone. ... cuff repair in one simple insertion maneuver. The ... of 5 mm and a small 2 mm ... hold a thin, bioabsorbable PLLA disc 5 mm ...
... The Bio-Corkscrews with NeedlePunch Needles are ... NeedlePunch instrument. The NeedlePunch Needles are preloaded ... housed inside the driver shaft. As the ... line is adjacent to the tissue before ...
... The Bio-FASTak is a 3 mm x 14 ... indications in the shoulder, knee, elbow and ankle. ... into the body of the anchor and provides ... metal anchors. This unique eyelet design allows the ...
Medicine Products: